Context Therapeutics Highlights CT-95 and CT-202 Programs at SITC Annual Meeting

Context Therapeutics presented two posters at the 2025 SITC Annual Meeting, highlighting its CT-95 and CT-202 programs. CT-95, a mesothelin x CD3 bispecific TCE, is in an ongoing Phase 1 trial with no cytokine release syndrome greater than Grade 2 and no dose-limiting toxicity observed. CT-202, a Nectin-4 x CD3 bispecific TCE, demonstrates potent preclinical activity with a favorable pharmacokinetic and safety profile, supporting its transition into clinical studies. Context anticipates providing initial Phase 1a data for CT-95 in mid-2026 and initiating a first-in-human trial for CT-202 in Q2 2026.